LLY Stock Cash Flow Statements

Eli Lilly and Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Eli Lilly and Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30

cash flows from operating activities
net income	5,660,500,000	2,759,300,000	4,409,800,000	970,300,000	2,967,000,000	2,242,900,000	2,189,700,000	-57,400,000	1,763,200,000	1,344,900,000	1,937,700,000	1,451,700,000	952,500,000	1,902,900,000	1,726,100,000	1,110,100,000	1,390,200,000	1,355,300,000	2,116,800,000	1,208,400,000	1,412,000,000	1,456,500,000	1,495,700,000	1,253,900,000	1,327,200,000	4,241,600,000	1,125,000,000	1,149,500,000	-259,900,000	1,217,400,000	-1,656,900,000	555,600,000	1,008,000,000	-110,800,000	771,800,000	778,000,000	747,700,000	440,100,000	478,400,000	799,700,000	600,800,000	529,500,000	733,500,000	727,900,000	1,203,100,000	1,206,200,000	1,548,000,000	1,326,600,000
adjustments to reconcile net income to cash flows from operating activities:
depreciation and amortization	478,500,000	462,800,000	484,800,000	466,800,000	414,400,000	400,600,000	387,700,000	411,000,000	366,300,000	362,300,000	375,000,000	362,900,000	348,900,000	435,700,000	445,700,000	382,300,000	369,300,000	350,300,000	367,500,000	358,400,000	324,400,000	273,600,000	340,700,000	288,000,000	247,400,000	356,500,000	345,500,000	415,500,000	425,200,000	422,800,000	411,900,000	372,900,000	395,600,000	386,900,000	344,600,000	392,800,000	373,700,000	385,500,000	343,400,000	358,300,000	368,500,000	357,500,000	348,400,000	348,800,000	349,000,000	363,900,000	381,500,000	369,700,000
change in deferred income taxes	-1,068,700,000	-391,600,000	-966,700,000	-429,800,000	-1,007,600,000	-279,000,000	-506,200,000	-844,300,000	-431,100,000	-559,400,000	10,400,000	-1,070,600,000	-618,400,000	-506,600,000	-92,500,000	-296,000,000	-294,700,000	-119,100,000	-200,700,000	159,700,000	-104,700,000	11,200,000	85,800,000	-12,100,000	61,100,000	-72,400,000	165,200,000	26,800,000	157,500,000	-22,700,000	-939,600,000	-143,400,000	166,300,000	128,800,000	88,700,000	182,200,000	138,000,000	30,600,000	-77,400,000	-4,500,000	-559,400,000	-107,100,000	27,700,000	93,500,000	608,700,000	249,900,000	-51,000,000	55,500,000
stock-based compensation expense	185,100,000	153,700,000	141,900,000	133,200,000	211,100,000	159,400,000	120,200,000	215,600,000	161,500,000	131,200,000	92,900,000	85,100,000	92,100,000	101,000,000	75,300,000	90,100,000	91,900,000	85,500,000	87,800,000	71,700,000	76,800,000	71,800,000	81,600,000	75,500,000	79,500,000	75,800,000	72,800,000	68,500,000	70,200,000	68,000,000	72,200,000	69,900,000	69,900,000	69,300,000	66,800,000	61,500,000	65,000,000	62,000,000	58,400,000	54,700,000	55,800,000	48,900,000	38,600,000	38,300,000	36,300,000	33,600,000	35,200,000	34,500,000
net investment losses				-112,400,000				64,500,000	65,800,000	14,200,000
acquired in-process research and development	153,800,000	1,571,700,000	189,200,000	2,826,400,000	154,300,000	110,500,000	622,600,000	2,975,100,000	97,100,000	105,000,000	168,900,000	19,000,000	80,000,000	153,000,000	376,600,000	174,000,000	25,000,000	299,300,000	366,300,000	0	241,800,000	52,300,000	0	77,700,000	25,000,000	136,900,000	329,400,000	30,000,000			50,000,000	205,000,000	0	857,600,000					199,000,000	0	80,000,000	256,000,000
other changes in operating assets and liabilities, net of acquisitions																												293,900,000	-662,100,000	-1,270,000,000		593,300,000	-123,500,000	-995,000,000
other operating activities	54,400,000	324,800,000	542,800,000	-32,100,000	-31,900,000	298,600,000	192,300,000	485,600,000	-550,700,000	168,300,000																																	67,700,000	5,100,000	21,300,000	7,000,000	9,200,000	41,500,000
net cash from operating activities	3,086,900,000	1,665,600,000	2,473,800,000	3,711,900,000	1,466,200,000	1,166,000,000	-311,900,000	2,189,500,000	631,900,000	1,730,600,000	1,579,700,000	2,184,800,000	820,700,000	2,499,200,000	2,156,500,000	1,631,300,000	1,775,500,000	1,697,400,000	1,815,200,000	1,806,600,000	2,495,400,000	382,400,000	1,963,700,000	1,510,100,000	1,051,500,000	311,300,000	1,448,700,000	2,121,800,000	1,517,500,000	436,500,000	1,743,500,000	1,881,100,000	1,651,100,000	339,900,000	2,116,900,000	1,659,200,000	1,401,800,000	-326,900,000	804,300,000	1,104,700,000	948,600,000	-84,800,000	1,053,900,000	272,300,000	1,991,600,000	1,637,200,000	379,400,000	1,544,300,000
capex	-1,697,100,000	-1,509,500,000	-1,496,000,000	-1,350,700,000	-1,224,800,000	-986,300,000	-1,070,600,000	-970,300,000	-738,200,000	-668,500,000	0	-617,200,000	-371,000,000	-365,400,000	0	-336,800,000	-381,300,000	-300,300,000	0	-393,100,000	-281,800,000	-258,300,000	0	-263,400,000	-240,300,000	-203,700,000	0	-269,800,000	-310,000,000	-236,500,000	0	-242,700,000	-221,600,000	-169,000,000	0	-227,500,000	-245,400,000	-154,300,000	0	-273,500,000	-223,900,000	-188,600,000	-254,900,000	-202,000,000	-253,800,000	-136,400,000	-157,900,000	-182,000,000
free cash flows	1,389,800,000	156,100,000	977,800,000	2,361,200,000	241,400,000	179,700,000	-1,382,500,000	1,219,200,000	-106,300,000	1,062,100,000	1,579,700,000	1,567,600,000	449,700,000	2,133,800,000	2,156,500,000	1,294,500,000	1,394,200,000	1,397,100,000	1,815,200,000	1,413,500,000	2,213,600,000	124,100,000	1,963,700,000	1,246,700,000	811,200,000	107,600,000	1,448,700,000	1,852,000,000	1,207,500,000	200,000,000	1,743,500,000	1,638,400,000	1,429,500,000	170,900,000	2,116,900,000	1,431,700,000	1,156,400,000	-481,200,000	804,300,000	831,200,000	724,700,000	-273,400,000	799,000,000	70,300,000	1,737,800,000	1,500,800,000	221,500,000	1,362,300,000
cash flows from investing activities
purchases of property and equipment	-1,697,100,000	-1,509,500,000	-1,496,000,000	-1,350,700,000	-1,224,800,000	-986,300,000	-1,070,600,000	-970,300,000	-738,200,000	-668,500,000
proceeds from sales of and distributions from noncurrent investments	204,300,000	71,600,000	55,600,000	67,900,000	179,600,000	70,500,000	31,900,000	87,800,000	106,500,000	281,900,000
purchases of noncurrent investments	-171,200,000	-196,700,000	-152,200,000	-275,000,000	-133,000,000	-117,100,000	-256,000,000	-131,400,000	-197,400,000	-146,000,000	-126,100,000	-222,700,000	-134,700,000	-116,700,000	-219,800,000	-207,000,000	-211,600,000	-291,500,000	-135,000,000	-68,900,000	-71,800,000	-83,000,000	-50,800,000	-50,100,000	-86,000,000	-60,600,000	-118,200,000	-43,200,000	-114,900,000	-561,600,000	-872,000,000	-1,380,800,000	-1,412,900,000	-945,900,000	-705,300,000	-1,371,500,000	-1,552,500,000	-716,700,000	-553,100,000	-840,600,000	-908,400,000	-924,400,000	-2,824,500,000	-2,770,200,000	-3,763,400,000	-4,614,700,000	-1,861,400,000	-2,030,200,000
cash paid for acquisitions, net of cash acquired			0	0											0	0	0	-747,400,000	0	0	0	-849,300,000	0	0	0	-6,917,700,000					0	0	0	-882,100,000	0	0			4,700,000	-11,100,000	0	-5,276,700,000						0
purchases of in-process research and development	-106,800,000	-1,757,000,000	-251,200,000	-2,820,100,000	-178,000,000	-96,500,000	-580,500,000	-3,030,900,000	-98,100,000	-235,000,000	-54,900,000	-3,000,000	-80,000,000	-491,800,000	-102,800,000	-118,800,000	-150,000,000	-191,800,000	-364,800,000	-22,000,000	-241,400,000	-13,000,000	0
other investing activities	-64,100,000	39,300,000	-158,800,000	-169,800,000	95,600,000	-65,200,000	-22,800,000	-666,200,000	456,800,000	40,300,000	61,900,000	-157,000,000	22,100,000	-133,400,000	27,000,000	-53,200,000	72,400,000	-21,900,000	86,500,000	12,200,000	-47,300,000	51,400,000	232,000,000	-141,500,000	46,400,000	-385,600,000	-2,500,000	-143,500,000	-24,100,000	-21,200,000	-37,800,000	-61,100,000	-109,100,000	-7,800,000	-55,000,000	-43,300,000	4,700,000	-36,500,000	-30,900,000	-41,000,000	-59,000,000	-2,700,000	-19,600,000	-11,900,000	-35,800,000	-37,300,000	-18,400,000	49,700,000
net cash from investing activities	-1,834,900,000	-3,352,300,000	-1,920,500,000	-4,004,700,000	-2,198,700,000	-1,177,600,000	-2,924,300,000	-3,080,500,000	-459,100,000	-688,800,000	-860,500,000	-923,400,000	-463,900,000	-1,013,800,000	-379,000,000	-616,500,000	-483,300,000	-1,283,500,000	-674,100,000	-313,500,000	-210,400,000	-1,060,900,000	-41,400,000	-423,800,000	61,000,000	-7,678,700,000	-659,000,000	-398,100,000	3,133,400,000	-170,300,000	1,652,900,000	-1,758,000,000	-2,248,900,000	-1,429,600,000	-1,178,100,000	-794,700,000	-1,020,900,000	-145,400,000	253,700,000	-570,100,000	182,400,000	160,800,000	-468,900,000	388,400,000	-943,800,000	-1,251,700,000	1,355,100,000	-132,700,000
cash flows from financing activities
dividends paid	-1,347,000,000	-1,346,300,000	-1,168,300,000	-1,170,500,000	-1,172,400,000	-1,169,200,000	-1,018,100,000	-1,016,200,000	-1,017,800,000	-1,017,200,000	-884,400,000	-882,200,000	-883,700,000	-885,500,000	-773,300,000	-770,400,000	-768,300,000	-774,800,000	-670,000,000	-671,600,000	-674,200,000	-671,300,000	-587,200,000	-587,400,000	-598,000,000	-637,200,000	-572,600,000	-572,600,000	-579,300,000	-587,300,000	-548,300,000	-547,700,000	-548,700,000	-547,400,000	-541,100,000	-537,900,000	-541,200,000	-538,300,000	-533,300,000	-526,300,000	-539,800,000	-527,900,000	-526,900,000	-524,100,000	-527,700,000	-533,000,000	-531,100,000	-544,200,000
net change in short-term borrowings	1,602,800,000	-1,848,700,000	3,042,300,000	-3,089,400,000	3,400,100,000	-5,204,800,000	4,594,400,000	1,595,000,000	0	-1,498,000,000	-243,300,000	-375,900,000	1,617,500,000	499,700,000	-2,500,000	-197,800,000	200,000,000	-3,700,000	-579,900,000	-678,900,000	-1,984,100,000	1,748,700,000	-63,500,000	-505,400,000	-286,100,000	1,850,400,000	99,200,000	-2,048,400,000	953,800,000	-1,202,500,000	170,700,000	1,101,100,000	-371,800,000	497,500,000	1,294,900,000	-300,000												-500,000
proceeds from issuance of long-term debt	0	6,461,000,000	0	4,964,600,000	0	6,452,500,000	0	0	0	3,958,500,000					0				0	1,073,700,000			2,108,100,000	0	0	4,448,300,000	0				0	0			0	0			100,000	0	2,272,600,000	2,182,000,000	0	992,900,000
repayments of long-term debt			0	0							0	0	-849,900,000	-710,100,000	-100,000				-200,000	0	0	-276,300,000	-2,266,100,000	-100,000	-200,000	-600,000,000	-7,600,000	0	-201,200,000	-800,300,000	0	-100,000	-300,000	-630,200,000
purchases of common stock	-692,200,000	-1,200,000,000	-2,053,900,000				0	0	0	-750,000,000	0	0	0	-1,500,000,000	-750,000,000	0			0	0	0	-500,000,000	-300,000,000	-600,000,000	0	-3,500,000,000	-1,100,000,000	-1,000,000,000	-950,700,000	-1,100,000,000	-99,900,000	0			-300,000,000	0	0	-300,100,000	-252,900,000	-61,100,000	-124,900,000	-310,600,000	-145,000,000	-55,000,000	0	0	-1,198,100,000
other financing activities	-30,400,000	-686,300,000	-45,500,000	-47,300,000	-8,000,000	-389,800,000	-31,600,000	-6,800,000	-15,600,000	-281,000,000	-13,700,000	-5,200,000	-7,600,000	-282,400,000	-600,000	-500,000	-14,900,000	-279,900,000	-41,400,000	-2,300,000	-3,500,000	-194,400,000	-4,900,000	0	-1,500,000	-193,700,000	-58,700,000	-83,700,000	-54,000,000	-176,400,000	-64,800,000	-52,600,000	-51,400,000	-195,600,000	-179,000,000	-59,300,000	-85,600,000	23,100,000	111,500,000	-5,000,000	-12,700,000	45,400,000	-1,100,000	-6,900,000
net cash from financing activities	-1,244,900,000	1,379,700,000	-225,400,000	211,300,000	1,555,500,000	-311,300,000	3,544,700,000	572,000,000	-1,033,400,000	412,300,000	-1,141,400,000	-1,263,300,000	-123,700,000	-2,878,300,000	-1,526,500,000	-463,200,000	-1,083,200,000	-1,058,400,000	-1,291,500,000	-279,100,000	-1,673,200,000	106,700,000	-1,113,600,000	-1,692,900,000	-885,800,000	1,367,800,000	-1,639,700,000	432,700,000	-831,400,000	-3,866,500,000	-542,300,000	500,700,000	1,059,900,000	-875,700,000	274,800,000	-597,600,000	579,400,000	-816,400,000	-679,600,000	-595,200,000	-943,200,000	-701,200,000	-702,500,000	-595,100,000	-529,000,000	-533,800,000	-1,730,100,000	-544,700,000
effect of exchange rate changes on cash and cash equivalents	275,500,000	131,900,000	-428,500,000	226,900,000	-59,600,000	-35,500,000	129,300,000	5,300,000	9,200,000	24,800,000	-128,200,000	-3,600,000	-69,400,000	33,600,000	-220,700,000	16,600,000	8,600,000	-10,200,000	212,200,000	16,200,000	54,300,000	-66,700,000	-35,000,000	-119,800,000	27,100,000	37,800,000	-111,800,000	-13,700,000	-86,500,000	148,400,000	-42,200,000	30,600,000	-9,100,000	200,000	-120,500,000	-15,900,000	-29,900,000	-70,100,000	49,200,000	-16,100,000	62,900,000	-181,600,000	-4,800,000	-7,800,000	63,600,000	-1,800,000	-86,600,000	106,500,000
net increase in cash and cash equivalents			-100,600,000	145,400,000	763,400,000	-358,400,000	437,800,000	-313,700,000	-851,400,000	1,478,900,000					30,300,000	568,200,000			61,800,000	1,230,200,000			773,700,000	-726,400,000			-961,800,000	2,142,700,000														-806,800,000		57,800,000				973,400,000
cash and cash equivalents at january 1	0	3,268,400,000		0	0	2,818,600,000		0	0	2,067,000,000		0	0	3,818,500,000		0	0	3,657,100,000		0	0	2,337,500,000		0	0	7,998,200,000		0	0	6,536,200,000		0	0	4,582,100,000		0	0	3,666,400,000		0	0	3,871,600,000	0	3,830,200,000	0	0	4,018,800,000	0
cash and cash equivalents at june 30
net investment (gains) losses		149,100,000				-15,800,000					-256,400,000	130,800,000	119,500,000	426,100,000
other changes in operating assets and liabilities, net of acquisitions and divestitures		-3,364,200,000		-9,800,000	-1,399,100,000	-1,751,200,000		793,300,000	-840,200,000	164,100,000		939,100,000	-72,100,000	-45,500,000		-666,500,000	221,200,000	-102,800,000		249,400,000	926,500,000	-1,408,100,000		-247,300,000	-802,100,000	-714,300,000										184,100,000	29,600,000	-1,429,500,000		26,200,000	227,400,000	-913,700,000	-80,000,000	-941,300,000	-226,800,000	-223,400,000	-1,048,100,000
net decrease in cash and cash equivalents		-175,100,000										-5,500,000	163,700,000	-1,359,300,000				-654,700,000				-638,500,000				-5,961,800,000				-3,451,900,000		654,400,000	453,000,000	-1,965,200,000		251,000,000	930,400,000	-1,358,800,000		-76,700,000						-150,100,000	-82,200,000
cash and cash equivalents at march 31		3,093,300,000				2,460,200,000				3,545,900,000				2,459,200,000				3,002,400,000				1,699,000,000				2,036,400,000				3,084,300,000				2,616,900,000				2,307,600,000				3,064,800,000		3,888,000,000			3,936,600,000
investment (gains) losses
gains on sale of product rights			-123,100,000				-25,000,000
other changes in operating assets and liabilities, net of acquisitions and divestitures:
receivables—increase
inventories—increase
prepaid expenses and other assets—increase
accounts payable and other liabilities—increase
proceeds from sales and maturities of short-term investments			41,600,000	31,900,000	34,000,000	41,400,000	37,000,000	45,600,000	48,100,000	61,500,000	38,300,000	25,500,000	30,900,000	26,700,000	800,000	25,300,000	17,300,000	4,000,000	10,900,000	7,600,000	74,400,000	36,800,000	20,300,000	26,900,000	53,500,000	35,900,000	17,000,000	38,800,000	2,046,000,000	450,700,000	2,532,300,000	642,600,000	509,200,000	1,168,400,000	396,100,000	320,500,000	403,800,000	521,600,000	576,000,000	300,500,000	778,100,000	507,200,000	722,800,000	1,166,900,000	396,200,000	374,400,000	1,607,500,000
purchases of short-term investments			-29,900,000	-19,800,000	-24,400,000	-24,400,000	-19,000,000	-19,400,000	-36,800,000	-23,000,000	-42,400,000	-32,100,000	-18,300,000	-14,600,000	-55,600,000	-1,300,000	-7,200,000	-19,400,000	0				-8,600,000	0	-400,000	-33,700,000	0	0	0	-112,200,000	-415,900,000	-1,090,300,000	-1,594,100,000	-289,400,000	-901,700,000	-160,400,000	-166,900,000	-98,400,000	-78,000,000	-175,700,000	-422,700,000	-165,800,000	-401,700,000	-402,800,000	-263,000,000	-202,500,000	-313,100,000
proceeds from sale of product rights			70,400,000				0																																0	0	0	410,000,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
cash and cash equivalents at september 30
debt extinguishment loss															0																									0
other assets—increase
other non-cash operating activities											87,200,000	266,800,000	-81,800,000	32,600,000	6,700,000	185,100,000	188,500,000	131,100,000	121,700,000	-96,500,000	383,600,000	-74,900,000	193,200,000	74,400,000	113,400,000	-32,300,000	151,300,000	137,600,000	162,100,000	21,000,000	75,800,000	227,800,000	134,800,000	3,100,000	83,300,000	60,600,000	51,200,000	184,400,000	227,100,000	-129,700,000	-11,400,000	-49,600,000
income taxes payable—increase
proceeds from sales of noncurrent investments											90,600,000	83,100,000	87,100,000	81,400,000	262,800,000	75,300,000	177,100,000	284,800,000	183,000,000	162,100,000	357,500,000	54,500,000	111,400,000	82,000,000	332,800,000	83,600,000	64,800,000	49,600,000	3,084,600,000	310,500,000	899,100,000	579,300,000	579,600,000	528,000,000	479,200,000	687,500,000	580,400,000	338,900,000	796,600,000	521,300,000	1,154,300,000	596,200,000
net purchases of property and equipment												-617,200,000	-371,000,000	-365,400,000		-336,800,000	-381,300,000	-300,300,000		-393,100,000	-281,800,000	-258,300,000		-263,400,000	-240,300,000	-203,700,000		-269,800,000	-310,000,000	-236,500,000		-242,700,000	-221,600,000	-169,000,000		-227,500,000	-245,400,000	-154,300,000		-273,500,000	-223,900,000	-188,600,000	-254,900,000	-202,000,000	-253,800,000	-136,400,000	-157,900,000	-182,000,000
gain related to disposition of elanco																							0	0	0	-3,680,500,000
gain on sale of antibiotic business in china
net investment gains															93,100,000	247,000,000	-215,900,000	-302,200,000	-529,000,000	-144,500,000
cash distributed to elanco upon disposition
cash received for sale of antibiotic business in china
net proceeds from elanco initial public offering																											0
adjustments to reconcile net incometo cash flows from operating activities:
purchase of in-process research and development																									-45,000,000	-196,900,000		-30,000,000				-205,000,000	0	-831,800,000						-50,000,000	-136,000,000	-200,000,000
proceeds from disposals of property and equipment
disposals of property and equipment
cash released for pending acquisition
net proceeds from (payments for) terminations of interest rate swaps
cash released
purchase of product rights																																											-46,300,000	-25,000,000
net payments for terminations of interest rate swaps																																				0
restricted cash released for acquisition																																								0	0	5,405,600,000
repayment of long-term debt																																				-100,000				-1,400,000	-1,947,700,000	-1,500,000	-31,800,000	-1,002,000,000	-1,300,000	-800,000	-900,000	0
net change in short term borrowings																																						-1,100,000		-1,400,000	-590,700,000	-2,088,600,000
income related to termination of the exenatide collaboration with amylin pharmaceuticals, inc.
net proceeds (payments) for terminations of interest rate swaps
payments for terminations of interest rate swaps																																										-206,300,000
adjustments to reconcile net incometo cash flows from operating activities
net realized investment gains
impairment charges, indefinite lived intangibles
acquired in-process research and development, net of tax
income related to termination of the exenatide collaboration with amylin
proceeds from terminations of interest rate swaps
changes in operating assets and liabilities, net of acquisitions:
cash restricted for pending acquisition
proceeds from prepayment of revenue-sharing obligation
income related to termination of the exenatide collaboration
proceeds from sales and maturities of noncurrent investments																																												2,633,400,000	3,019,700,000	3,364,800,000	2,098,400,000	1,106,100,000
net change in loan to collaboration partner
income related to transfer of exenatide rights																																														0	-495,400,000
income related to prepayment of revenue-sharing obligation
other changes in operating assets and liabilities																																																488,300,000
net change in short-term investments																																																-351,400,000
cash and cash equivalents at sept 30
loan to collaboration partner

We provide you with 20 years of cash flow statements for Eli Lilly and stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Eli Lilly and stock. Explore the full financial landscape of Eli Lilly and stock with our expertly curated income statements.

The information provided in this report about Eli Lilly and stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.